Wellcome Trust: The Scientist’s Endowment and VC’s Quiet Giant
The Wellcome Trust is one of those rare institutions that straddles two worlds with equal weight: science and capital. Born from the fortune of pharmaceutical pioneer Sir Henry Wellcome, it started in 1936 as a traditional charitable trust. For decades, its main role was to fund research, but when the Trust sold its pharmaceutical company stake in the 1980s and 1990s—cashing out of what eventually became GlaxoSmithKline—it unlocked billions to be managed as an endowment.
That endowment has since grown into more than £38 billion , and it’s not run conservatively. Instead, Wellcome has built a reputation as one of the savviest institutional investors in the world, with long-term annualized returns often cited above 14%. Its investment arm doesn’t just dabble in public markets; it goes deep into private markets, venture capital, buyouts, and hedge funds . Around £8 billion sits in VC funds alone , and another £3.9 billion in buyout funds .
What makes Wellcome unusual among charities is how actively it plays the LP game. Instead of spraying capital across the market, it targets only the very best managers—especially early-stage venture funds. The strategy is clear: back the firms at the cutting edge of innovation, the same innovation that feeds into its scientific mission. That means its money sits alongside names like Sequoia, ARCH Venture Partners, Venrock, and Abingworth. Sometimes, Wellcome even co-invests directly in startups, turning up in cap tables of companies like Instacart, DoorDash, and Klarna .
The connection between its investments and mission is deliberate. By funding labs and scientists on one hand, and betting on the venture ecosystem on the other, Wellcome positions itself both as a patron of discovery and as a shareholder in the companies that translate science into products. This dual approach gives it a flywheel effect: steady investment returns fuel its grantmaking (around £1 billion annually ), while its grantmaking helps seed the very breakthroughs that top VCs race to commercialize.
Today, under CEO John-Arne Røttingen, Wellcome is sharpening its focus on three big areas—infectious disease, mental health, and climate & health. But in the background, the investment arm remains one of the best-kept secrets of the venture world: a perpetual, sovereign-wealth-sized LP , whose checkbook and time horizon dwarf almost everyone else’s.
